Pharmaceutical - Anti-virals


Current filters:


Popular Filters

176 to 200 of 305 results

Merck & Co and Gilead highlight new data at international HIV meeting


US pharma giant Merck & Co (NYSE: MRK)presented new data at the 11th International Congress on HIV and…

Anti-viralsBiotechnologyCompleraGilead SciencesIsentressMerck & CoPharmaceuticalResearchStribild

ViiV Healthcare's dolutegravir shows promise in hard-to-treat HIV patients


ViiV Healthcare, and HIV/AIDS company jointly owned by GlaxoSmithKline (LSE: GSK), Pfizer (NYSE: PFE)…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalResearchShionogiViiV Healthcare

Gilead HIV drugs Atripla and Truvada to be listed in New Zealand


Following a consultation, New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval…

Anti-viralsAsia-PacificAtriplaBiotechnologyGilead SciencesPharmaceuticalPricingRegulationTruvada

Bristol-Myers daclatasvir combo achieves 94% response in hep C patients


US drug major Bristol-Myers Squibb (NYSE: BMY) has, for the first time, released Phase II data demonstrating…

Anti-viralsasunaprevirBMS-791325Bristol-Myers SquibbdaclatasvirPharmaceuticalResearch

Incivo plus peginterferon and ribavirin positive for co-infected hep C and HIV patients, says Janssen


US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Infectious Diseases - Diagnostics BVBA presented…

Anti-viralsBiotechnologyIncivoJanssenJohnson & JohnsonPharmaceuticalResearch

EU approves label change for Bristol-Myer's Baraclude


US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the European Commission has approved a Baraclude…

Anti-viralsBaracludeBristol-Myers SquibbEuropePharmaceuticalRegulation

Revised terms for ViiV Healthcare and Shionogi HIV partnership


UK pharma giant GlaxoSmithKline (LSE: GSK) says that Healthcare, its HIV/AIDS joint venture with Pfizer,…

Anti-viralsdolutegravirGlaxoSmithKlineMergers & AcquisitionsPfizerPharmaceuticalShionogiViiV Healthcare

BioCryst and Presidio to merge, creating new competitor in HCV arena


USA drugmaker BioCryst Pharmaceuticals (Nasdaq: BCRX) has signed a definitive accord to acquire privately…

Anti-viralsBioCryst PharmaceuticalsMergers & AcquisitionsPharmaceuticalPresidio Pharmaceuticals

US FDA agrees to review Sanofi Pasteur's new quadrivalent influenza vaccine


Sanofi Pasteur, the vaccines division of Sanofi (Euronext: SAN) says it has filed a supplemental Biologics…

Anti-viralsNorth AmericaPharmaceuticalRegulationSanofiSanofi PasteurVaccines

Merck & Co in-licenses portfolio targeting HCMV from AiCuris for up to $570 million


US pharma giant Merck & Co (NYSE: MRK) has entered into an exclusive worldwide licensing agreement with…

AiCurisAnti-viralsletermovirLicensingMerck & CoPharmaceutical

Abbott Lab's HCV regimen achieves near complete cure rates in mid-stage trial


USA-based Abbott Laboratories (NYSE ABT) announced strong initial results from "Aviator," a Phase IIb…

Abbott LaboratoriesAnti-viralsPharmaceuticalResearch

Indonesian government overrides patents on seven HIV and hepatitis drugs


In a move that was announced in early September but which just came to light last week, the government…


Australia's Benitec to acquire US RNAi firm Tacere


Australia-based Benitec Biopharma (ASX: BLT) said last Friday that it has executed an agreement to acquire…

Anti-viralsBenitec BiopharmaBiotechnologyMergers & AcquisitionsPharmaceuticalTacere Therapeutics

Gilead's Truvada as HIV prevention to carry stronger FDA warning label


The USA-based non-profit HIV/AIDS advocacy AIDS Healthcare Foundation (AHF) welcomed the news yesterday…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationTruvada

HIV drug nelfinavir shows efficacy in mouse models of HER2+ breast cancer


The HIV protease inhibitor nelfinavir, marketed by Swiss drug major Roche as Viracept, can be used to…


Achillion Pharma moves up as a contender in the HCV market, GlobalData believes


On September 27, Achillion Pharmaceuticals (Nasdaq: ACHN) released news of positive results surrounding…

ACH-3102Achillion PharmaceuticalsAnti-viralsBiotechnologyMergers & AcquisitionsPharmaceuticalResearch

Astellas to use Abbott's CMV assay for vaccine trial


US health care major Abbott Laboratories (NYSE: ABT) says that it has signed an agreement to collaborate…

Abbott LaboratoriesAnti-viralsAstellas PharmaPharmaceuticalResearchTransVaxVaccines

Bristol-Myers drops hep C pill on patient safety issues


US drug major Bristol-Myers Squibb (NYSE: BMY) has discontinued development of BMS-986094 (formerly known…

Anti-viralsBiotechnologyBMS-986094Bristol-Myers SquibbPharmaceuticalRegulationResearch

NanoViricides' flu drug candidates demonstrate oral effectiveness


US drug developer NanoViricides (OTCBB: NNVC) says that anti-influenza drug candidates under its FluCide…


AHF calls for Gilead's Quad HIV pill to be put on "prior authorization" status


In what may be an unprecedented move on drug pricing and access, advocates from the AIDS Healthcare Foundation…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalPricingQuadRegulation

176 to 200 of 305 results

Back to top